ライフサイエンスコーパス: myelotoxicity

1 b')2 at different activities (close to acute myelotoxicity).

2 b')2 at different activities (close to acute myelotoxicity).

3 vity groups the reduction was close to acute myelotoxicity.

4 d to evaluate the radioimmunotherapy-related myelotoxicity.

5 plete remission rates of 35% to 42%, without myelotoxicity.

6 had limited success because of dose-limiting myelotoxicity.

7 ntial value of several factors in predicting myelotoxicity.

8 ology were used to assess hematotoxicity and myelotoxicity.

9 counts at nadir was used as an indicator of myelotoxicity.

10 utics for preventing chemotherapy-associated myelotoxicity.

11 time and absence of pathways contributing to myelotoxicity.

12 w progenitor cells may contribute to benzene myelotoxicity.

13 ionship between topotecan exposure (AUC) and myelotoxicity.

14 correlation between the red marrow dose and myelotoxicity.

15 ndertaken to determine the factors affecting myelotoxicity after radioimmunotherapy (RAIT) with 131I-

16 In patients with prostate cancer, myelotoxicity after treatment with (177)Lu-J591 can be p

17 The lack of correlation between myelotoxicity and (90)Y-J591 BMrad may be due to several

18 es < or = 250 cGy resulted in < or = grade 2 myelotoxicity and a red marrow dose of 450 cGy resulted

19 combining these drugs increases the risk of myelotoxicity and may require granulocyte colony-stimula

20 observed vulnerability to antibiotic-induced myelotoxicity and prolonged neutropenia after nonmyeloab

21 gamma-H2AX values are associated with acute myelotoxicity and secondary blood malignancy may be wort

22 GK-MGMT) protects animals in vivo from acute myelotoxicity associated with CNU treatment.

23 (> or =100 mg/kg) there was no difference in myelotoxicity between the wild-type and HRN mice.

24 kely to have marrow targeting, prediction of myelotoxicity by conventional body and blood contributio

25 m (a key determinant of azathioprine-induced myelotoxicity) by using TPMT enzyme activity to establis

26 Myelotoxicity can be ameliorated by peripheral blood ste

27 clonal antibodies, it has been reported that myelotoxicity cannot be predicted on the basis of the am

28 e title compound (14) showed reduced in vivo myelotoxicity compared to linezolid in a 14-day safety s

29 very of an oxazolidinone possessing improved myelotoxicity compared to linezolid, linezolid-like effi

30 Myelotoxicity consisting of thrombocytopenia or neutrope

31 In radioimmunotherapy, myelotoxicity due to bone marrow radiation-absorbed dose

32 oactivity method was not a good predictor of myelotoxicity for non-marrow-targeting (90)Y-antibody th

33 However, myelotoxicity from (90)Y-antibody therapy often correlat

34 The percentage of patients with myelotoxicity (grade 3-4) increased with increasing dose

35 the correlation of marrow radiation dose and myelotoxicity has not been well documented.

36 The lack of adverse myelotoxicity implies that the absorbed dose delivered f

37 450 cGy resulted in reversible grade 3 or 4 myelotoxicity in 3 of 6 patients.

38 d leukemic transformation, and assessment of myelotoxicity in preclinical drug development requires a

39 t is important to predict and possibly avoid myelotoxicity in radionuclide therapies.

40 Myelotoxicities included grade > or = 3 granulocytopenia

41 hat 4-OH-CPA Cmax may determine its level of myelotoxicity indicates that the therapeutic index could

42 of red marrow radiation is important because myelotoxicity is often dose limiting in radioimmunothera

43 filtration rate, and common toxicity such as myelotoxicity is prevented with the use of hematopoietic

44 cent chemotherapy as significant factors for myelotoxicity may be important in the future design of c

45 re resistant to antifolates, suggesting that myelotoxicity occurs late in hematopoietic development.

46 okines to circumvent the acute dose-limiting myelotoxicity of cancer treatment, little is known about

47 AART appears to significantly potentiate the myelotoxicity of CDE chemotherapy.

48 lysis of the toxicity experiments showed the myelotoxicity of CPA was found to be closely correlated

49 sed to accurately predict absorbed doses and myelotoxicity of radioimmunotherapy with (177)Lu-cG250.

50 edical history, disease characteristics, and myelotoxicity of the chemotherapy regimen.

51 edical history, disease characteristics, and myelotoxicity of the chemotherapy regimen.

52 explore a possible role for apoptosis in the myelotoxicity of the phenolic metabolites of benzene.

53 Moreover, CD-160130 had no myelotoxicity on human bone marrow-derived cells.

54 ps are active in this area either to improve myelotoxicity profile of linezolid or to expand the spec

55 Myelotoxicity resulting from the accumulation of 212Pb i

56 There was no significant myelotoxicity, stomatitis, or alopecia.

57 statin with cyclophosphamide would have less myelotoxicity than combinations using other purine analo

58 Prediction of myelotoxicity using marrow dose estimated from blood was

59 Myelotoxicity was dose-limiting, and its severity was re

60 Myelotoxicity was not significant at any dose.

61 toxicity whereas only temporary and moderate myelotoxicity was observed with 7.4 MBq.

62 , its use is somewhat limited because of its myelotoxicity when used long term (>21 days).

63 study provides a simple model for predicting myelotoxicity with reasonable accuracy in most patients.